Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy.

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Gligorov, J.
Harris, L.
Kostler, W. J.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VAMC, Lebanon, PA USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Tenon Hosp, Paris, France
[6] Yale Univ, New Haven, CT 06520 USA
[7] Univ Hosp Vienna, Vienna, Austria
[8] Humboldt Univ, Berlin, Germany
[9] Biol Specialiste Ctr Lutte Contre, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3S / 3S
页数：1
相关论文
共 50 条
  • [31] The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.
    Eustace, Alexi
    Toomey, Sinead
    Fay, Joanna
    Teiserkiene, Ausra
    Milewska, Malgorzata
    Kay, Elaine
    O'Connor, Darran
    Fagan, Ailis
    Young, Leonie S.
    O'Donovan, Norma
    Walshe, Janice Maria
    Hill, Arnold D.
    Kennedy, M. John
    Power, Colm
    Duke, Deirdre
    Hambly, Niamh
    Gallagher, William M.
    Crown, John
    Hennessy, Bryan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy.
    Orlova, Rashida
    Beliak, Natalia P.
    Kutukova, Svetlana
    Zhukova, Natalia, V
    Avramenko, Inna
    Popova, Natalia, V
    Ivanova, Anastasia
    Androsova, Alexandra
    Zorina, Ekaterina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Predictivity of serum HER-2/NEU and EGFR concentrations for clinical outcome to the monocloncal anti-HER/2-neu antibody trastuzumab plus combination chemotherapy in metastatic breast cancer.
    Lueftner, DI
    Henschke, P
    Amin, R
    Geppert, R
    Wernecke, KD
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S56 - S57
  • [34] Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer
    Petersen, Eva Rabing Brix
    Sorensen, Patricia Diana
    Jakobsen, Erik Hugger
    Madsen, Jonna Skov
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (07) : 1483 - 1492
  • [35] A Novel Detection Methodology for HER2 Protein Quantitation in Clinical Samples: Correlation with Pathologic Response to Trastuzumab-Based Neoadjuvant Therapy.
    Turner, Bradley M.
    Buscaglia, Brandon
    Goda, Hideki
    Mcmahon, Loralee
    Natori, Takako
    Okada, Hisatake
    Soukiazian, Armen
    Nakano, Yasushi
    Hicks, David
    MODERN PATHOLOGY, 2018, 31 : 110 - 111
  • [36] Comparison of serum and tissue HER-2/neu expression in metastatic breast cancer patients prior to Herceptin therapy.
    Kish, LA
    Goldblatt, J
    Neaman, I
    Kaplan, IV
    Lin, D
    Schwartz, D
    Ghani, F
    Armstrong, G
    Schwartz, KM
    CLINICAL CHEMISTRY, 2001, 47 (06) : A132 - A132
  • [37] Automated assay for HER-2/neu in serum
    Payne, RC
    Allard, JW
    Anderson-Mauser, L
    Humphreys, JD
    Tenney, DY
    Morris, DL
    CLINICAL CHEMISTRY, 2000, 46 (02) : 175 - 182
  • [38] Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
    Lipton, A
    Ali, SM
    Leitzel, K
    Demers, L
    Chinchilli, V
    Engle, L
    Harvey, HA
    Brady, C
    Nalin, CM
    Dugan, M
    Carney, W
    Allard, J
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1467 - 1472
  • [39] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Eto, Tetsuya
    Narita, Yukiya
    Taniguchi, Hiroya
    Ura, Takashi
    Ando, Masashi
    Tajika, Masahiro
    Niwa, Yasumasa
    Yatabe, Yasushi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 807 - 813
  • [40] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
    Shigenori Kadowaki
    Toshiki Masuishi
    Tetsuya Eto
    Yukiya Narita
    Hiroya Taniguchi
    Takashi Ura
    Masashi Ando
    Masahiro Tajika
    Yasumasa Niwa
    Yasushi Yatabe
    Kei Muro
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 807 - 813
12345